Crescom

(May 15, 2020)

 MediAI-BA, an artificial intelligence-based bone age analysis software, has been officially launched by Crescom.

In a clinical trial conducted in 2019, MediAI-BA achieved the world's highest level of accuracy with an average absolute difference of 0.39 years (95% confidence interval 0.33 – 0.45) from the reference standard. In March of this year, the Ministry of Food and Drug Safety has issued medical device approval for MediAI-BA.

 Crescom's MediAI-BA applies patented technologies that integrates the strengths of GP and TW3 methods and greatly improving the accuracy.

Also, Crescom has received CE certification and ISO13485:2016 (international medical device quality management certification) in 2019. MediAI-BA has been completed registration with the European Ministry of Food and Drug Safety, and is in the process of advancing into the Middle East and Southeast Asia in collaboration with various organizations.

Crescom, which is developing everything from musculoskeletal medical imaging to cerebrovascular analysis solutions, said, “We want to provide convenient and accurate solutions to medical professionals through innovative solutions to help them reduce their workload and focus more on preserving life and promoting health.”